RNAi Nanoparticle System for Murine Cancer Models
Use InVivoPlex® to:
- Study in vivo function of tumor genes in a clinically relevant fashion
- Prioritize the most promising gene targets for drug discovery
- Study multi-gene inhibition or gene interactions with chemotherapy
- Validate candidate RNAi or gene cancer therapeutics in vivo
- Use InVivoPlex® -Tumor to study vascularized tumor models
- Use InVivoPlex® -cRGD to study murine models of neovasculature
InVivoPlex® self-assembling, RNAi nanoparticles form with a protective coat and optimal size for selective localization in vascularized tumors through an Enhanced Permeability and Retention mechanism (EPR). The easy to use kit provides everything needed to use the polymeric reagent to form the nanoparticles with your in vitro optimized RNAi, siRNA, shRNA, plasmids or even combinations. The reagent can reveal in vivo activity of candidate therapeutic targets, simulating effects of an antagonist drug before costly drug discovery.
- Simple to use kit that forms siRNA nanoparticles <50 nm, and stable for 1 week
- Highly selective uptake by vascularized murine tumor models, minimual lung uptake
- Low toxicity and low levels of cytokine induction, minimizing off-target effects
- Clinical relevance: multiple dose regimens, dose response, effect simulates targeted therapy
- Delivers siRNA oligonucleotides, plasmids, and combinations
Tumor Targeted, Therapeutic RNAi Nanoparticle Capabilities
- Tumor Selectivity: Delivery is directed to vascularized tumor tissue, away from organs
- Repeat Dosing: Administer 3 times per week, without toxicity
- Dose Response: Evaluate dosages from 1 mg/kg to 6 mg/kg
- Many Models: Many murine cancer models exhibit EPR active tumors
- Multiple Cargos: siRNA, plasmids, and combinations can be delivered
Top: InVivoPlex® -Tumor luciferase plasmid nanoparticles given iv selectively target vascularized subcutaneous tumors in xenograft murine cancer models, without complicating lung or other organ activity typical of non-targeted in vivo transfection reagents.
Bottom: InVivoPlex® -Tumor siRNA nanoparticle treatment by iv, 3 times per week for two weeks, inhibits xenograft tumor growth. Left: pan human siRNA (Qiagen). Right: InVivoActTM hVEGF – equivalent to inhibition by the approved hVEGF mAb therapeutic.
Simple to Use , Complete Kit
- Simple Assembly: Add aqueous nucleic acid to NP Reagent Vial drop wise while stirring
- Cargo Flexibility: You select the cargo: siRNA, shRNA, or expression plasmid
- Convenient: Nanoparticles can be prepared once each week for administration
- Complete Kit: Mixing system and all buffers, including Vehicle Control, are provided
- Accessory Kits: Specialized RNAi to facilitate tumor uptake and gene activity studies
Points To Consider
Use InVivoPlex® to evaluate gene or protein inhibition in vivo
Evaluate experimental therapeutic targets in vivo with InVivoPlex®
Use InVivoPlex® to evaluate gene combinations or interaction with chemotherapeutics
InVivoPlex® Kits enable translation of RNAi studies to murine models of cancer, with the objective to allow studies producing clinically relevant information on tumor gene function, candidate targets for therapeutic intervention, and in vivo validation of RNAi therapeutic candidates. The InVivoPlex® Kits supply all the required buffers and the nanoparticle forming reagent, along with everything needed for specialized mixing with user supplied nucleic acid agents form targeted nanoparticles that localize in targeted tissue in murine models of cancer, as well as vehicle control buffer for a control treatment group of mice. An important advantage of the reagent is the feature that it allows the user to prepare the nanoparticles with their experimental RNAi agent, and the capability to use a wide variety of RNAi agents as well as to perform combination RNAi studies. InVivoPlex® Kits are available for preparation of nanoparticle samples for treatment of small, medium, or large groups of mice. Kits for other group sizes can be provided upon request.
To use InVivoPlex®, we recommend starting with a tissue uptake study to insure activity of the specific murine model to be used, or its optimization activity. The InVivoTrakTM fluorescent labeled companion products are available to facilitate these studies. The InVivoTrakTM is available with either red or near IR fluorescent labels, and can be used with tumor homogenates in a fluorescence plate reader or with an NIR in vivo imaging instrument. InVivoTrakTM fluorescent tracer products are designed for use with small size group studies. The InVivoTrakTM Oligo products are designed for use with the small InVivoPlex® kit, to make fluorescent labeled nanoparticles for testing EPR tumor uptake. InVivoTrakTM is available with either red or near IR fluorescent labels. The InVivoTrakTM Carrier products are designed for use with unlabeled RNAi or with InVivoTrakTM oligo products for dual label tracer studies.
For studies of RNAi activity, we recommend multi-dose studies over several weeks with multiple treatment groups that include negative and positive controls. The InVivoActTM negative and positive RNAi agent companion products are available to facilitate these studies. InVivoActTM products are designed for use with the large InVivoPlex® Kit, and are available in forms to provide a negative RNAi treatment and to provide positive RNAi treatments that inhibit a clinically validated therapeutic target gene, such as VEGF or EGFR.
For more information, please contact us by phone or email.